Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2014-04-02 Regulatory Filings
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings
2014-04-02 English
FORM 4 -
Director's Dealing
2014-03-26 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes upcoming presentations of clinical study data at a conference, which is a typical disclosure in an 8-K. The document is short (3567 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or quarterly report, nor an earnings release. It is not a proxy, voting result, or management change announcement. The document is a regulatory filing reporting a material event, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-03-24 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce major events that shareholders should know about. The text describes an event where the European Commission lifted the suspension of a marketing authorization for a drug, which is a significant corporate event but not a financial report or earnings release. The document is short (2584 characters) and is an announcement of an event rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-03-18 English
THERAVANCE, INC. 8K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 14, 2014. It announces positive results from Phase 3 clinical studies related to a pharmaceutical product. The content is primarily a press release incorporated by reference, describing an event rather than detailed financial data or comprehensive reporting. The document length is 2904 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial statement or management discussion present. The document is not an earnings release, annual report, or interim report. It is a regulatory filing used to disclose material events promptly. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2014-03-14 English
THERAVANCE, INC. 8K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a press release about the completion of patient recruitment for a clinical study (SUMMIT) related to a drug developed by Theravance and GlaxoSmithKline. There is no detailed financial data, management discussion, or full report attached. The document is short (2756 characters) and primarily announces an event rather than providing a full report or detailed financial information. It includes a press release as an exhibit, which is typical for an 8-K filing. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-03-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.